Multi-institutional Phase 2/3 Trial of Valproic Acid in Patients With Moderate to Severe Traumatic Brain Injury
| Registry | NCT07166393, acronym VIBRANT |
|---|---|
| Status | Not yet recruiting |
| Phase | Phase 2 / Phase 3 |
| Study type | Interventional; randomized, parallel, masking: triple, treatment |
| Enrollment | 432 (Estimated) |
| Sponsor | Northwestern University (Other); collaborators: United States Department of Defense |
| Conditions | Moderate Traumatic Brain Injury (TBI), Severe Traumatic Brain Injury |
| Interventions | Valproic Acid (VPA), Standard of care treatment + normal saline (Drug, other) |
| Dates | start 2027-05-01 (estimated), primary completion 2031-05-01 (estimated), completion 2031-12-01 (estimated), first posted 2025-09-10, last updated 2026-08-13 |
| Locations | 8 sites in United States |
Related Papers Related Patents Related Grants Related Experts
All trials for Moderate Traumatic Brain Injury (TBI) All trials for Severe Traumatic Brain Injury All trials of Valproic Acid (VPA) All trials of Standard of care treatment + normal saline
The long-term goal of the clinical trial is to develop effective, safe, and easily administered life-saving treatments for patients with moderate to severe traumatic brain injury (TBI).
Patients with moderate to severe TBI will randomly receive either:
1. Standard of care treatment and normal saline
2. Standard of care treatment and one dose of valproic acid (VPA) at a lower dose or a higher dose
The specific aim is to determine whether giving VPA at either a 50 mg/kg dose or a 100 mg/kg is safe (as measured by adverse events after treatment) in patients with moderate to severe TBI due to brain bruises.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Control | Placebo comparator | Other: Standard of care treatment + normal saline | Standard of Care + Normal Saline (0.9% sodium chloride solution) |
| Experimental | Experimental | Drug: Valproic Acid (VPA) | Standard of care treatment + one dose of VPA (in 250 ml 0.9% sodium chloride solution) in the following two doses: * Lower dose VPA: 50 mg/kg * Higher dose VPA: 100 mg/kg |
Sex: All, ages: 18 Years to 65 Years
Inclusion Criteria: 1. Male or female between the ages of 18 and 65 years. 2. Body Mass Index between 18 kg/m2 and 35 kg/m2. 3. Females must be surgically sterilized, postmenopausal, or have a negative urine pregnancy test. 4. Moderate to severe TBI: Glasgow Coma Scale (GCS) 3-12. 5. Cerebral trauma confirmed on the initial CT scan with radiographic findings consistent with Brain Injury Guidelines category 3 (BIG 3) criteria Exclusion Criteria: 1. Persons with known history of adverse reactions to VPA 2. Persons with known history of hepatitis B or C or clinical history of hepatic dysfunction, pancreatitis, or renal insufficiency. 3. Persons with a known history of thrombocytopenia. 4. Persons with platelet count less than 100,000 per microliter of blood. 5. Persons with 2nd or 3rd degree burns of any size and location. 6. Female subjects who are pregnant or lactating. 7. Persons who are currently incarcerated or are in police custody. 8. Persons with inadequate venous access. 9. Treatment cannot start within 120 minutes from the onset of injury 10. Non-survivable injuries in the estimation of the attending trauma surgeon. 11. Interfacility transfers 12. The time of injury is unknown 13. Patients in hemorrhagic shock with a systolic blood pressure of <90 mmHg on initial evaluation. 14. Persons with a known "do not resuscitate" order prior to randomization 15. Persons with a research "opt out" bracelet 16. Persons who are currently enrolled in another clinical trial. 17. Greater than 90 minutes between the onset of injury and arrival to the hospital
| Facility | City | Country | Status |
|---|---|---|---|
| University of Alabama at Birmingham | Birmingham, Alabama | United States | |
| University of Arizona | Tucson, Arizona | United States | |
| University of Southern California | Los Angeles, California | United States | |
| University of California, Davis | Sacramento, California | United States | |
| Oregon Health & Science University | Portland, Oregon | United States | |
| Vanderbilt University Medical Center | Nashville, Tennessee | United States | |
| University of Texas Southwestern | Dallas, Texas | United States | |
| Medical College of Wisconsin | Milwaukee, Wisconsin | United States |